Observations placeholder
Sandostatin
Identifier
015707
Type of Spiritual Experience
Number of hallucinations: 87
Background
A description of the experience
Octreotide is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), pituitary tumors that secrete thyroid stimulating hormone (thyrotropinoma), diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive intestinal peptide-secreting tumors (VIPomas).
Octreotide is also given as an infusion for management of acute haemorrhage from esophageal varices in liver cirrhosis on the basis that it reduces portal venous pressure, though current evidence suggests that this effect is transient and does not improve survival.
On Jan, 12, 2017 18,430 people reported to have side effects when taking Sandostatin. Among them, 46 people (0.25%) have Hallucination
On Jan, 07, 2017 15,800 people reported to have side effects when taking Sandostatin Lar. Among them, 41 people (0.26%) have Hallucination
On Dec, 24, 2016 18,430 people reported to have side effects when taking Sandostatin. Among them, 2,451 people (13.3%) have Death
Time on Sandostatin when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 17.76% | 28.57% | 20.85% | 8.49% | 19.31% | 4.25% | 0.77% |
On Dec, 24, 2016 15,800 people reported to have side effects when taking Sandostatin Lar. Among them, 2,162 people (13.68%) have Death
Time on Sandostatin lar when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 14.71% | 29.41% | 20.17% | 9.24% | 21.01% | 4.62% | 0.84% |